A Non-Inferiority, Randomized controlled trial of Alternate-Day versus Multiple-Daily-Dose Oral Iron for Iron Deficiency Anemia in Patients with Non-Dialysis Chronic Kidney Disease

Navamindradhiraj University0 个研究点目标入组 86 人开始时间: 2026年7月1日最近更新: 2026年8月3日

适应症

试验速览

暂无简介。

•Patients with chronic kidney disease (CKD) stages 3 to 5 with an estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2 who have not yet initiated kidney replacement therapy (KRT).
•Hemoglobin less than 12 g/dL in females and less than 13 g/dL in males.
•Serum ferritin less than 100 ng/mL (micrograms/L) and transferrin saturation (TSAT) less than 40 percent, or serum ferritin 100 to 300 ng/mL (micrograms/L) and TSAT less than 25 percent.
•Age 18 years or older.

•Patients with hematologic disorders or conditions causing pre-existing anemia, including thalassemia (confirmed by hemoglobin typing), hemolytic anemia, bone marrow disorders, or liver cirrhosis (Child-Pugh score 9 or higher).
•Patients with other inflammatory conditions associated with anemia, including active malignancy or active autoimmune disease.
•Patients with diseases or conditions associated with impaired nutrient absorption, including inflammatory bowel disease or short bowel syndrome.
•Hemoglobin less than 7 g/dL.
•History of blood transfusion within the previous 1 month, iron therapy within the previous 3 months, or erythropoiesis-stimulating agent (ESA) therapy within the previous 1 month.
•Active bleeding that has not been controlled.
•Pregnant or breastfeeding women.
•History of hypersensitivity to iron preparations.
•Patients expected to require kidney replacement therapy within 3 months.

发起方